Literature DB >> 16388492

Association between severe respiratory syncytial virus infection and IL13/IL4 haplotypes.

Beena Puthothu1, Marcus Krueger, Johannes Forster, Andrea Heinzmann.   

Abstract

Respiratory syncytial virus (RSV) infection has been implicated in the pathogenesis of bronchial asthma. In both diseases, interleukin (IL)-4 and IL-13 play important roles. By investigating IL4 and IL13 polymorphisms in 131 children with severe RSV infection and 270 control subjects, we found an association between IL13 polymorphism -1112C/T and severe RSV infection (P = .026). Furthermore, certain haplotypes showed an even stronger association with severe RSV infection (P = .0008). The results suggest that there is a common genetic background in children with severe RSV infection and bronchial asthma. More studies are needed to clarify whether RSV infection provokes asthma or whether RSV infection occurs in children who are genetically predisposed to a pronounced T helper 2 immune response and subsequently develop bronchial asthma.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16388492     DOI: 10.1086/499316

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  33 in total

1.  Transforming growth factor beta is a major regulator of human neonatal immune responses following respiratory syncytial virus infection.

Authors:  Natalie J Thornburg; Bryan Shepherd; James E Crowe
Journal:  J Virol       Date:  2010-10-06       Impact factor: 5.103

2.  Immunomodulation with IL-4R alpha antisense oligonucleotide prevents respiratory syncytial virus-mediated pulmonary disease.

Authors:  Michael J Ripple; Dahui You; Srinivasa Honnegowda; Joseph D Giaimo; Andrew B Sewell; David M Becnel; Stephania A Cormier
Journal:  J Immunol       Date:  2010-09-22       Impact factor: 5.422

3.  Exploring the origins of asthma: Lessons from twin studies.

Authors:  Simon Francis Thomsen
Journal:  Eur Clin Respir J       Date:  2014-09-01

4.  Host transcription profiles upon primary respiratory syncytial virus infection.

Authors:  Riny Janssen; Jeroen Pennings; Hennie Hodemaekers; Annemarie Buisman; Marijke van Oosten; Lia de Rond; Kemal Oztürk; Jan Dormans; Tjeerd Kimman; Barbara Hoebee
Journal:  J Virol       Date:  2007-03-21       Impact factor: 5.103

5.  Limited type I interferons and plasmacytoid dendritic cells during neonatal respiratory syncytial virus infection permit immunopathogenesis upon reinfection.

Authors:  Stephania A Cormier; Bishwas Shrestha; Jordy Saravia; Greg I Lee; Li Shen; John P DeVincenzo; Young-In Kim; Dahui You
Journal:  J Virol       Date:  2014-06-11       Impact factor: 5.103

6.  IL-4Rα on CD4+ T cells plays a pathogenic role in respiratory syncytial virus reinfection in mice infected initially as neonates.

Authors:  Dahui You; Nico Marr; Jordy Saravia; Bishwas Shrestha; Greg I Lee; Stuart E Turvey; Frank Brombacher; De'Broski R Herbert; Stephania A Cormier
Journal:  J Leukoc Biol       Date:  2013-03-29       Impact factor: 4.962

Review 7.  Human genetic factors and respiratory syncytial virus disease severity.

Authors:  Isao Miyairi; John P DeVincenzo
Journal:  Clin Microbiol Rev       Date:  2008-10       Impact factor: 26.132

Review 8.  Human Genetic Determinants of Viral Diseases.

Authors:  Adam D Kenney; James A Dowdle; Leonia Bozzacco; Temet M McMichael; Corine St Gelais; Amanda R Panfil; Yan Sun; Larry S Schlesinger; Matthew Z Anderson; Patrick L Green; Carolina B López; Brad R Rosenberg; Li Wu; Jacob S Yount
Journal:  Annu Rev Genet       Date:  2017-08-30       Impact factor: 16.830

9.  Characterization of respiratory syncytial virus M- and M2-specific CD4 T cells in a murine model.

Authors:  Jie Liu; Tracy J Ruckwardt; Man Chen; Teresa R Johnson; Barney S Graham
Journal:  J Virol       Date:  2009-03-04       Impact factor: 5.103

10.  Risk factors for respiratory syncytial virus bronchiolitis hospital admission in New Zealand.

Authors:  K Grimwood; C Cohet; F J Rich; S Cheng; C Wood; N Redshaw; C W Cunningham; N Pearce; J R Kirman
Journal:  Epidemiol Infect       Date:  2008-01-04       Impact factor: 2.451

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.